Search

everythinglearnresearchcommunity

for

Search:↓

New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

Thalidomide works best for skin lupus not helped by antimalarials, but has many side effects; other treatments are less effective, especially if patients also have systemic lupus.

Glucocorticoids for progressive muscular dystrophy in children don't improve muscle strength or function but do increase certain side effects.

Topical calcipotriol may help treat alopecia areata, especially in those with low vitamin D.

Sunlight exposure improved a patient's skin condition, and there may be a link between a certain disease and skin growths; a leukemia treatment caused changes in hair color and growth.

The combination therapy effectively improved acne keloidalis nuchae.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Pfizer found that pantolactam-based compounds can reduce sebum (skin oil) production when applied topically.

Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.

Antimalarial agents are effective for LPP, and intralesional steroids are effective for FFA.

Oclacitinib effectively treated a diabetic cat's severe skin issues without raising glucose levels, and surgery fixed eyelid fusion.

Low-dose isotretinoin combined with pulsed azithromycin cleared acne in most patients, with mild side effects.

Intralesional triamcinolone is more effective than topical betamethasone for treating localized alopecia areata.

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

Acitretin improved monilethrix symptoms temporarily, but they returned after stopping treatment.

Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.

Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.

High-dose UVA-1 therapy improves symptoms and skin condition in sclerosing skin disease.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.

Intralesional methotrexate and triamcinolone acetonide are more effective than Vitamin D3 for treating alopecia areata.

LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.

DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.

Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.

Higher activity in lichen planopilaris is linked to certain immune and tissue genes.

A protein called lfTSLP is important in causing allergic and other skin diseases and could be a target for treatment.

Mesalazine showed limited effectiveness in treating children with severe alopecia areata.

Dupilumab may help treat hair loss and skin color loss in some patients with atopic dermatitis.

Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.